CoQ10 treatment in inadequately treated hypertensive patients with the metabolic syndrome.

A double-blind, randomised, placebo controlled, 12-week cross-over study to assess the effect of Coenzyme Q10 treatment on 24hr mean ambulatory systolic and diastolic blood pressure in inadequately treated hypertensive patients with the metabolic syndrome.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000241932

Enrollment

Registered

2011-03-04

Start date

2008-12-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

CoQ10 has been reported to lower blood pressure. We are giving supplemental CoQ10 to 30 participants with the metabolic syndrome and uncontrolled high blood pressure, despite medication, to determine whether CoQ10 can further lower their blood pressure, and reduce their risk of serious disease.

Interventions

Coenzyme Q10 (100mg twice daily) or placebo (twice daily) for 12 weeks via oral capsule, followed by a 4-week washout period, then 12 weeks of the alternate 'treatment'.

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

25 Years to 75 Years

Healthy volunteers

Inclusion criteria

Hypertension (average sitting systolic BP of >139 mmHg or >129/80 if patient has type II diabetes) and stabilised on antihypertensives for at least 1 month. The metabolic syndrome

Exclusion criteria

Uncontrolled hypertension Cerebrovascular accident within 12 months prior Taking warfarin treatment or antioxidant vitamin supplements

Outcome results